SCM
STOK icon

Sterling Capital Management’s Stoke Therapeutics STOK Stock Holding History

Sterling Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Buy
318
+20
+7% +$656 ﹤0.01% 2358
2025
Q4 		$9.46K Buy
298
+189
+173% +$5.68K ﹤0.01% 2630
2025
Q3 		$2.56K Buy
109
+10
+10% +$171 ﹤0.01% 2940
2025
Q2 		$1.12K Buy
99
+62
+168% +$589 ﹤0.01% 3044
2025
Q1 		$246 Hold
37
– – ﹤0.01% 3062
2024
Q4 		$408 Hold
37
– – ﹤0.01% 3058
2024
Q3 		$455 Buy
+37
New +$524 ﹤0.01% 2916

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sterling Capital Management's STOK Position: Q1 2026 in Review

Sterling Capital Management increased its Stoke Therapeutics (STOK) stake by 6.7% in Q1 2026, buying an estimated $656 and bringing the position to 318 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Sterling Capital Management first reported a position in STOK in Q3 2024 and has held it in 7 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Sterling Capital Management held 318 shares of Stoke Therapeutics worth $10.4K as of Q1 2026.
  • Sterling Capital Management bought 20 Stoke Therapeutics shares in Q1 2026, an estimated $656.
  • Stoke Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2358 holding.
  • Sterling Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.